Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

July 6, 2021 11:57 UTC

 

 
 

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m. ET. A live webcast of the event will be available to clients of Cowen.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

Contacts

Investor and Media Contact:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377

 
 

Source: Aptinyx Inc.

Back to news